Quest Diagnostics. 2011. Licenses and Accreditation. http://www.questdiagnostics.com/brand/company/b_comp_licenses.html (accessed November 21, 2011).

Ransohoff, D. F. 2003. Gene-expression signatures in breast cancer. New England Journal of Medicine 348(17):1716.

Ransohoff, D. F. 2004. Rules of evidence for cancer molecular-marker discovery and validation. Nature Reviews Cancer 4(4):309-314.

Ransohoff, D. F. 2005. Bias as a threat to the validity of cancer molecular-marker research. Nature Reviews Cancer 5:142-148.

Ransohoff, D. F., and M. L. Gourlay. 2010. Sources of bias in specimens for research about molecular markers for cancer. Journal of Clinical Oncology 28(4):698-704.

Review of Genomic Predictors for Clinical Trials from Nevins, Potti, and Barry. 2009. Durham, NC: Duke University.

Rosenberg, S., M. R. Elashoff, P. Beineke, S. E. Daniels, J. A. Wingrove, W. G. Tingley, P. T. Sager, A. J. Sehnert, M. Yau, W. E. Kraus, K. Newby, R. S. Schwartz, S. Voros, S. G. Ellis, N. Tahirkhelli, R. Waksman, J. McPherson, A. Lansky, M. E. Winn, N. J. Schork, E. J. Topol, and for the PREDICT (Personalized Risk Evaluation and Diagnosis In the Conorary Tree) Investigators. 2010. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Annals of Internal Medicine 153(7):425-434.

Shak, S. 2011. Case Study: Oncotype DX Breast Cancer Assay. Presentation at the Workshop of the IOM Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Washington, DC, March 30.

Simon, R., M. D. Radmacher, K. Dobbin, and L. M. McShane. 2003. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. Journal of the National Cancer Institute 95(1):14-18.

Teutsch, S. M., L. A. Bradley, G. E. Palomaki, J. E. Haddow, M. Piper, N. Calonge, D. Dotson, M. P. Douglas, and A. O. Berg. 2009. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genetics in Medicine 11(1):3-14.

van de Vijver, M. J., Y. D. He, L. J. van ‘t Veer, H. Dai, A. A. M. Hart, D. W. Voskuil, G. J. Schreiber, J. L. Peterse, C. Roberts, M. J. Marton, M. Parrish, D. Atsma, A. Witteven, A. M. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E. T. Rutgers, S. F. Friend, and R. Bernards. 2002. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347(25):1999-2009.

van ‘t Veer, L. J. 2011. Case study—MammaPrint. Presented at Meeting 2 of the Committee on Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Washington, DC, March 30.

van ‘t Veer, L. J., H. Dai, M. J. van de Vijver, Y. D. He, A. A. M. Hart, M. Mao, H. L. Peterse, K. van der Kooy, M. J. Marton, A. T. Wittereveen, G. J. Schreiber, R. M. Kerkoven, C. Roberts, P. S. Linsley, R. Bernards, and S. F. Friend. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(31):530-536.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement